JP5730862B2 - オクロバクトラム・インターメディウムのリポ多糖類および哺乳動物の免疫刺激剤としてのそれらの使用 - Google Patents

オクロバクトラム・インターメディウムのリポ多糖類および哺乳動物の免疫刺激剤としてのそれらの使用 Download PDF

Info

Publication number: JP5730862B2
Authority: JP; Japan
Prior art keywords: lps; composition according; composition; animals; lmg3306
Prior art date: 2009-06-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2012513476A

Other languages

English (en)

Japanese (ja)

Other versions

JP2012528805A (ja

Inventor

フアン・イングナシオ・オベヘロ・ギサソラ

マヌエル・フレスノ・エスクデロ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Laboratorios Ovejero SA

Original Assignee

Laboratorios Ovejero SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-06-04

Filing date

2009-12-31

Publication date

2015-06-10

2009-12-31 Application filed by Laboratorios Ovejero SA filed Critical Laboratorios Ovejero SA

2012-11-15 Publication of JP2012528805A publication Critical patent/JP2012528805A/ja

2015-06-10 Application granted granted Critical

2015-06-10 Publication of JP5730862B2 publication Critical patent/JP5730862B2/ja

Status Expired - Fee Related legal-status Critical Current

2029-12-31 Anticipated expiration legal-status Critical

Links

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Transplantation (AREA)
Toxicology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP2012513476A 2009-06-04 2009-12-31 オクロバクトラム・インターメディウムのリポ多糖類および哺乳動物の免疫刺激剤としてのそれらの使用 Expired - Fee Related JP5730862B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
ESP200930265		2009-06-04
ES200930265A ES2352780B2 (es)	2009-06-04	2009-06-04	Lipopolisacárido de ochrobactrum intermedium contra la sepsis.
PCT/EP2009/009342 WO2010139352A1 (en)	2009-06-04	2009-12-31	Lipopolysaccharide of ochrobactrum intermedium and their use as immunostimulant of mammalians

Publications (2)

Publication Number	Publication Date
JP2012528805A JP2012528805A (ja)	2012-11-15
JP5730862B2 true JP5730862B2 (ja)	2015-06-10

Family

ID=41796455

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2012513476A Expired - Fee Related JP5730862B2 (ja)	2009-06-04	2009-12-31	オクロバクトラム・インターメディウムのリポ多糖類および哺乳動物の免疫刺激剤としてのそれらの使用

Country Status (20)

Country	Link
US (1)	US9241954B2 (es)
EP (1)	EP2437754B1 (es)
JP (1)	JP5730862B2 (es)
KR (1)	KR20120061045A (es)
CN (1)	CN102802639A (es)
AU (1)	AU2009347459A1 (es)
BR (1)	BRPI0924393A2 (es)
CA (1)	CA2763266A1 (es)
CL (1)	CL2011003033A1 (es)
CO (1)	CO6470857A2 (es)
CU (1)	CU24041B1 (es)
EA (1)	EA025766B1 (es)
ES (2)	ES2352780B2 (es)
IL (1)	IL216560A0 (es)
MX (1)	MX2011012934A (es)
NZ (1)	NZ596599A (es)
PL (1)	PL2437754T3 (es)
SG (1)	SG176660A1 (es)
WO (1)	WO2010139352A1 (es)
ZA (1)	ZA201200021B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103937722B (zh) *	2014-04-24	2016-10-26	烟台地元生物科技有限公司	中间苍白杆菌及微生物菌剂和它们的应用
CN106754562B (zh) *	2017-02-14	2020-06-02	南京中医药大学	一种高产细菌多糖的菌株及其发酵中药废弃物制备多糖的方法
CN106755186B (zh) *	2017-02-14	2020-03-31	南京中医药大学	一种中间苍白杆菌胞外多糖及其在土壤改良方面的应用
CN109182159B (zh) *	2018-07-27	2021-04-23	华南农业大学	一种n-酰基高丝氨酸内酯淬灭菌及其在病害防控中的应用
WO2020227159A2 (en) *	2019-05-03	2020-11-12	Flagship Pioneering Innovations V, Inc.	Methods of modulating immune activity
CN111053789A (zh) *	2019-11-26	2020-04-24	湖南营养树生物科技有限公司	调节免疫系统的方法和组合物
RU2736933C1 (ru) *	2020-05-20	2020-11-23	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени Г.П. Сомова" (НИИ эпидемиологии и микробиологии имени Г.П. Сомова)	Адъювант
CN111909874B (zh) *	2020-08-17	2022-08-19	东北农业大学	一株生防菌i-5及其在防治紫花苜蓿根腐病中的应用
CN112625943B (zh) *	2020-12-02	2021-11-16	安徽农业大学	一种玉米用溶钾菌剂及其制备方法和应用
CA3208643A1 (en)	2021-01-18	2022-07-21	Conserv Bioscience Limited	Coronavirus immunogenic compositions, methods and uses thereof
WO2024159198A2 (en) *	2023-01-27	2024-08-02	Nagy Aurangzeb Nafees	Compositions and methods using tetrahydrocannabinol and compositions including same for treating indications involving inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5824310A (en) *	1991-10-22	1998-10-20	The United States Of America As Represented By The Department Of Health And Human Services	Lipopplysaccharide conjugate vaccines
GB9706930D0 (en)	1997-04-04	1997-05-21	Univ Glasgow	Leishmania vaccine
AU2001227889A1 (en)	2000-01-14	2001-07-24	The United States of America, represented by The Secretary, Department of Health & Human Services	Oligodeoxynucleotide and its use to induce an immune response
WO2009012166A1 (en) *	2007-07-13	2009-01-22	Infectious Disease Research Institute	Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis

2009
- 2009-06-04 ES ES200930265A patent/ES2352780B2/es active Active
- 2009-12-31 CA CA2763266A patent/CA2763266A1/en not_active Abandoned
- 2009-12-31 EA EA201190309A patent/EA025766B1/ru not_active IP Right Cessation
- 2009-12-31 WO PCT/EP2009/009342 patent/WO2010139352A1/en not_active Ceased
- 2009-12-31 EP EP09799043.6A patent/EP2437754B1/en active Active
- 2009-12-31 CN CN2009801603018A patent/CN102802639A/zh active Pending
- 2009-12-31 NZ NZ596599A patent/NZ596599A/xx not_active IP Right Cessation
- 2009-12-31 SG SG2011089620A patent/SG176660A1/en unknown
- 2009-12-31 JP JP2012513476A patent/JP5730862B2/ja not_active Expired - Fee Related
- 2009-12-31 PL PL09799043T patent/PL2437754T3/pl unknown
- 2009-12-31 AU AU2009347459A patent/AU2009347459A1/en not_active Abandoned
- 2009-12-31 ES ES09799043.6T patent/ES2653202T3/es active Active
- 2009-12-31 BR BRPI0924393A patent/BRPI0924393A2/pt active Search and Examination
- 2009-12-31 US US13/375,174 patent/US9241954B2/en active Active
- 2009-12-31 KR KR1020127000276A patent/KR20120061045A/ko not_active Ceased
- 2009-12-31 MX MX2011012934A patent/MX2011012934A/es unknown
2011
- 2011-11-23 IL IL216560A patent/IL216560A0/en unknown
- 2011-12-01 CL CL2011003033A patent/CL2011003033A1/es unknown
- 2011-12-02 CU CU2011000223A patent/CU24041B1/es active IP Right Grant
- 2011-12-02 CO CO11166480A patent/CO6470857A2/es active IP Right Grant
2012
- 2012-01-03 ZA ZA2012/00021A patent/ZA201200021B/en unknown

Also Published As

Publication number	Publication date
IL216560A0 (en)	2012-02-29
AU2009347459A1 (en)	2011-12-22
KR20120061045A (ko)	2012-06-12
EA201190309A1 (ru)	2012-05-30
US20120107352A1 (en)	2012-05-03
ZA201200021B (en)	2013-03-27
CN102802639A (zh)	2012-11-28
CA2763266A1 (en)	2010-12-09
BRPI0924393A2 (pt)	2016-09-06
US9241954B2 (en)	2016-01-26
ES2352780B2 (es)	2011-09-15
ES2653202T3 (es)	2018-02-06
SG176660A1 (en)	2012-01-30
CU24041B1 (es)	2014-11-27
WO2010139352A1 (en)	2010-12-09
EA025766B1 (ru)	2017-01-30
NZ596599A (en)	2013-08-30
CU20110223A7 (es)	2012-06-21
EP2437754B1 (en)	2017-09-20
MX2011012934A (es)	2012-04-30
CL2011003033A1 (es)	2012-07-06
PL2437754T3 (pl)	2018-03-30
ES2352780A1 (es)	2011-02-23
CO6470857A2 (es)	2012-06-29
JP2012528805A (ja)	2012-11-15
EP2437754A1 (en)	2012-04-11

Legal Events

Date	Code	Title	Description
2012-12-08	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121207
2014-03-12	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140311
2014-06-11	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140610
2015-02-04	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150203
2015-02-09	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150209
2015-03-04	TRDD	Decision of grant or rejection written
2015-03-11	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150310
2015-04-16	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150408
2015-04-17	R150	Certificate of patent or registration of utility model	Ref document number: 5730862 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2018-04-17	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP5730862B2 (ja)	2015-06-10	オクロバクトラム・インターメディウムのリポ多糖類および哺乳動物の免疫刺激剤としてのそれらの使用
US7892567B2 (en)	2011-02-22	Methods and compositions for immunization against chlamydial infection and disease
JP2023011840A (ja)	2023-01-24	異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
RU2623174C2 (ru)	2017-06-22	Вакцины и композиции против streptococcus pneumoniae
TW202003023A (zh)	2020-01-16	針對尿路感染之疫苗
JP2011512152A (ja)	2011-04-21	改善された溶解度を有するＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原
KR20120093141A (ko)	2012-08-22	폐렴구균(ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅ)에 대항하는 백신과 조성물
Pan et al.	2015	Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model
Del Campo et al.	2010	Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice
Gulati et al.	2019	Preclinical efficacy of a lipooligosaccharide peptide mimic candidate gonococcal vaccine. mBio 10: e02552-19
WO2015050178A1 (ja)	2015-04-09	鼻粘膜ワクチン組成物
US20220257752A1 (en)	2022-08-18	New use of cyclic dinucleotides
CA2275896A1 (en)	1998-07-02	Chlamydia vaccines
Oma et al.	2009	Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice
US20230102247A1 (en)	2023-03-30	Methods and compositions relating to ionic liquid adjuvants
EP2514438B1 (en)	2017-03-22	ADJUVANT CONTAINING ß-HEMATIN
KR20180074804A (ko)	2018-07-03	마이코플라즈마 감염증용 백신
HK1177588A (en)	2013-08-23	Lipopolysaccharide of ochrobactrum intermedium and their use as immunostimulant of mammalians
RU2683027C2 (ru)	2019-03-26	Поливалентная иммунизирующая и/или терапевтическая композиция для применения при бактериальных инфекциях или пищевом отравлении, в частности сальмонеллёзе, способ получения этой композиции, её применение и вакцина, содержащая эту композицию
JP2000507209A (ja)	2000-06-13	ボレリア・ブルグドフェリ（Ｂｏｒｒｅｌｉａｂｕｒｇｄｏｒｆｅｒｉ）抗原を投与するための組成物および方法
WO2006005943A1 (en)	2006-01-19	Phage screening assay
EA049499B1 (ru)	2025-03-28	Комбинация пневмококковых капсульных полисахаридов эпидемически значимых для евразийского региона серотипов (варианты), включающая её поливалентная вакцина (варианты) и способ получения высокоочищенных капсульных полисахаридов бактерии streptococcus pneumoniae
US20080226661A1 (en)	2008-09-18	Phage Screening Assay
MXPA06014880A (es)	2008-10-03	Propiedades potenciadoras adyuvantes e inmunes de productos naturales de onchocerca volvulus